Targeted protein degradation, particularly through proteolysis-targeting chimeras (PROTACs) has emerged as a revolutionary approach in drug discovery and development over the past two decades. This technology harnesses the cell’s natural protein degradation machinery to selectively eliminate disease-causing proteins, offering several advantages over traditional small molecule inhibitors. As the field rapidly advances, several key trends and […]